203 related articles for article (PubMed ID: 31159604)
1. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
[No Abstract] [Full Text] [Related]
2. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
[TBL] [Abstract][Full Text] [Related]
4. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
5. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.
Gall TMH; Belete S; Khanderia E; Frampton AE; Jiao LR
Am J Pathol; 2019 Jan; 189(1):71-81. PubMed ID: 30558725
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
[TBL] [Abstract][Full Text] [Related]
9. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
10. miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer.
Ko J; Bhagwat N; Black T; Yee SS; Na YJ; Fisher S; Kim J; Carpenter EL; Stanger BZ; Issadore D
Cancer Res; 2018 Jul; 78(13):3688-3697. PubMed ID: 29735554
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
[TBL] [Abstract][Full Text] [Related]
12. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.
Cohen JD; Javed AA; Thoburn C; Wong F; Tie J; Gibbs P; Schmidt CM; Yip-Schneider MT; Allen PJ; Schattner M; Brand RE; Singhi AD; Petersen GM; Hong SM; Kim SC; Falconi M; Doglioni C; Weiss MJ; Ahuja N; He J; Makary MA; Maitra A; Hanash SM; Dal Molin M; Wang Y; Li L; Ptak J; Dobbyn L; Schaefer J; Silliman N; Popoli M; Goggins MG; Hruban RH; Wolfgang CL; Klein AP; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Lennon AM
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10202-10207. PubMed ID: 28874546
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
[TBL] [Abstract][Full Text] [Related]
15. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
17. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma.
Li Z; Jiang P; Li J; Peng M; Zhao X; Zhang X; Chen K; Zhang Y; Liu H; Gan L; Bi H; Zhen P; Zhu J; Li X
Oncogene; 2018 Jul; 37(28):3822-3838. PubMed ID: 29643475
[TBL] [Abstract][Full Text] [Related]
19. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
[TBL] [Abstract][Full Text] [Related]
20. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
